Genprex (NASDAQ:GNPX) Trading Down 20.4% - Here's What Happened

Key Points

• Genprex's shares saw a significant decline of 20.4% during trading, dropping to a low of $10.11 and last trading at $11.15.
• The company has a consensus sell rating from analysts, with Weiss Ratings and Wall Street Zen both restating and upgrading to a "sell" rating, respectively.
• In its latest earnings report, Genprex reported an EPS of ($8.50), which surpassed analysts' expectations of ($35.50).

Shares of Genprex (NASDAQ:GNPX - Get Free Report) were down 20.4% during trading on Tuesday . The stock traded as low as $10.11 and last traded at $11.15. Approximately 131,805 shares were traded during trading, a decline of 37% from the average daily volume of 209,328 shares. The stock had previously closed at $14.00.

Analyst Upgrades and Downgrades

Several analysts have commented on GNPX shares. Weiss Ratings restated a "sell (e+)" rating on shares of Genprex in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Genprex to a "sell" rating in a report on Saturday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Sell".

Genprex Trading Down 20.4%

The stock's 50-day simple moving average is $0.23 and its 200 day simple moving average is $0.25.

Genprex (NASDAQ:GNPX - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($8.50) EPS for the quarter, topping analysts' consensus estimates of ($35.50) by $27.00. On average, equities analysts predict that Genprex will post -5.7 EPS for the current year.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.